The GOG Foundation, Inc. IDEA Commitment
Collaborating to make an Impact, Drive our mission to transform the standard of care in women’s cancers forward, Empower physicians and patients to improve Access to clinical trials and tomorrow’s drugs today.
GOG Efforts of Improving Access & Opportunity In Clinical Trials: Education
- GOG/SGO IDEA joint paper published in Gynecologic Oncology June 2023
- Represented GOG-F as Diversity Expert at GCIG first Endometrial Consensus Conference 11/2023 Korea
- IDEA will be included in consensus paper and incorporated in all future endometrial cancer trials development globally
- Will be representing GOG-F at GCIG IDEA meeting in Barcelona 3/2024
- Winter 2024 NRG Educational Symposium – IDEA: Inclusion, Diversity, Equity and Access of Underrepresented Patients to Clinical Trials
- IDEA Education Modules (commitment to IDEA, community engagement, study planning, study conduct, workforce development, accountability/advocacy) -Spring 2024
GOG Efforts of Improving Access & Opportunity In Clinical Trials: Access
- Maximize ways to increase enrollment of diverse patients by alleviating/removing social and financial barriers- GOG-P trial budgets all include financial compensation to address SDOH
- Minimize excessive testing/visits and pay close attention to medical criteria/ labs to not exclude patients during protocol development- IDEA call with all sponsors; all IIT’s should also be doing this
- Evaluate and include more community sites to increase trial access to diverse patient populations- actively collecting data on ongoing trials to evaluate sites and come up with a diversity score metric
- Working with advocacy group/organizations to promote clinical trials in the community- working with SHARE, ECANA, Clearity, Cervivor, etc.
GOG Efforts of Improving Access & Opportunity In Clinical Trials:Policy
- SGO Fly in- Advocated for DIVERSE Clinical Trials Act
- Food and Drug Omnibus Reform Act (FDORA)- signed into law Dec 2022, provisions for clinical trial diversity and modernization (diversity action plans, decentralized trials, & streamline trials)
- White house Office of Science and Technology Policy (OSTP) 10/23 leading whole- of-govt approach to bolster clinical trial capacity enabling more diverse participation- community outreach and diverse workforce
- Will continue to work with SGO, ASCO, AACI with respect to advocacy
GOG Efforts of Improving Access & Opportunity In Clinical Trials: Research
- Working with sponsors on education and review of diversity plans on phase 3 trials:
- Increase capturing / reporting of race, gender, sexual orientation, disaggregation of race and ethnicity
- Set enrollment goals appropriately
- Interim monitoring of goals
- Seeing improvements: NRG-GY018, RUBY/GOG-3031, KN-A18/GOG-3047
- Phase 3 IIT’s also have diversity plans (i.e., ROCC )
- GOG IDEA Study Chairs/PI on GOG-P trials
- Future plan to raise funds for competitive grant funding to sites to increase IDEA
The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG’s Access & Opportunity initiative:
